OBJECTIVE: To describe events leading to development of a professionwide consensus definition of medication therapy management (MTM) and attendant programs and services and present the document (definition, services, and program requirements) resulting from the process. DATA SOURCES: Author's own knowledge and records of events. SUMMARY: Following the late 2003 passage of the Medicare Prescription Drug Improvement and Modernization Act, the pharmacy profession had a need to act quickly to define MTM so that a consensus definition would be available as regulations implementing the Medicare Part D benefit were being written. The American Pharmacists Association facilitated this process by convening a broad working group of members and other involved parties to draft a preliminary definition. The Pharmacy Practice Activity Classification was used to check elements of the definition for consistency with services being offered in a wide variety of settings. A professionwide stakeholders conference was then convened with representatives from each of 11 national pharmacy organizations. This group, following a daylong meeting in late May 2004 and several weeks of e-mail messages and conference calls, finalized the MTM definition, which was then approved by the chief executive officers of all 11 groups. CONCLUSION: Through the extraordinary efforts of the numerous organizations and participants, the MTM Services Definition is one that is applicable within diverse pharmacy practice segments, whose services are feasible for a majority of practitioners to implement, and whose elements are supported by a profession-wide consortium of 11 national professional pharmacy organizations. This historic achievement is the first step on a journey to find the best ways to effectively deliver MTM services to patients.
OBJECTIVE: To describe events leading to development of a professionwide consensus definition of medication therapy management (MTM) and attendant programs and services and present the document (definition, services, and program requirements) resulting from the process. DATA SOURCES: Author's own knowledge and records of events. SUMMARY: Following the late 2003 passage of the Medicare Prescription Drug Improvement and Modernization Act, the pharmacy profession had a need to act quickly to define MTM so that a consensus definition would be available as regulations implementing the Medicare Part D benefit were being written. The American Pharmacists Association facilitated this process by convening a broad working group of members and other involved parties to draft a preliminary definition. The Pharmacy Practice Activity Classification was used to check elements of the definition for consistency with services being offered in a wide variety of settings. A professionwide stakeholders conference was then convened with representatives from each of 11 national pharmacy organizations. This group, following a daylong meeting in late May 2004 and several weeks of e-mail messages and conference calls, finalized the MTM definition, which was then approved by the chief executive officers of all 11 groups. CONCLUSION: Through the extraordinary efforts of the numerous organizations and participants, the MTM Services Definition is one that is applicable within diverse pharmacy practice segments, whose services are feasible for a majority of practitioners to implement, and whose elements are supported by a profession-wide consortium of 11 national professional pharmacy organizations. This historic achievement is the first step on a journey to find the best ways to effectively deliver MTM services to patients.
Authors: Junling Wang; C Daniel Mullins; Lawrence M Brown; Ya-Chen Tina Shih; Samuel Dagogo-Jack; Song Hee Hong; William C Cushman Journal: Health Serv Res Date: 2010-05-24 Impact factor: 3.402
Authors: Junling Wang; Ya-Chen Tina Shih; Yolanda Qin; Theo Young; Zachary Thomas; Christina A Spivey; David K Solomon; Marie Chisholm-Burns Journal: Am Health Drug Benefits Date: 2015 Jul-Aug
Authors: Kacie L McPherson; Omolola A Adeoye-Olatunde; Jayna M Osborne; William R Doucette; Stephanie A Gernant; Heather Jaynes; Shobha Phansalkar; Alissa L Russ-Jara; Margie E Snyder Journal: J Am Pharm Assoc (2003) Date: 2020-01-25
Authors: Gerald Cochran; Adam J Gordon; Craig Field; Jennifer Bacci; Ranjita Dhital; Thomas Ylioja; Maxine Stitzer; Thomas Kelly; Ralph Tarter Journal: Res Social Adm Pharm Date: 2015-05-08
Authors: Kelly R Reveles; Eric M Mortensen; Jim M Koeller; Kenneth A Lawson; Mary Jo V Pugh; Sarah A Rumbellow; Jacqueline R Argamany; Christopher R Frei Journal: Pharmacotherapy Date: 2018-02-22 Impact factor: 4.705